查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1474860

PARP抑制剂生物标记市场规模、份额、趋势分析报告：按产品、服务、应用、地区、细分市场预测，2024-2030年

PARP Inhibitor Biomarkers Market Size, Share & Trends Analysis Report By Product (Kits, Assays), By Services (BRCA 1&2 Testing, HRD Testing), By Application, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

PARP抑制剂生物标记市场成长与趋势：

Grand View Research最新报告显示，预计到2030年，全球PARP抑制剂生物标记市场规模将达到16.021亿美元，预计2024年至2030年复合年增长率为8.54%。

乳癌发生率上升是 PARP 抑制剂生物标记市场扩张的关键因素。根据世界卫生组织 2022 年发表的一篇论文，癌症患者的盛行率正在上升，估计有 2,000 万新患者和 970 万人死亡。儘管取得了进展，对抗癌症的斗争仍然很艰难，估计有 5,350 万人在诊断后五年内存活下来。此外，女性乳癌已成为严重问题，占全球病例数第二位，达 230 万例（11.6%），死亡人数为 67 万人（6.9%）。值得注意的是，在受访的 185 个国家中，有 157 个国家的女性最为普遍。

基因组技术的进步极大地促进了PARP抑制剂生物标记的开发和改进。根据 NCBI 2021 年 8 月发表的论文，这些进展将使研究人员能够识别和检验预测患者对 PARP 抑制剂反应的生物标记物，从而促进个人化治疗策略。一项研究开发了一种 3D 功能测定法，以识别预测高恶性浆液性卵巢(HGSOC) 患者对聚 ADP-核糖聚合酵素抑製剂 (PARPis) 反应的生物标记。这种方法可以更精确、更全面地了解细胞如何在生理相关环境中对 PARP 抑制剂做出反应。

治疗和管理支出的增加正在推动市场成长。根据 BioMed Central Ltd 于 2022 年 9 月发表的一篇报导，乳癌和卵巢癌的特点是由几个因素决定的，包括诊断阶段、使用的特定治疗方法以及与癌症治疗相关的整体医疗费用。受到几个因素的影响。所提供的资讯来源提供了对治疗的经济负担和支出增加的驱动因素的深入了解。乳癌和卵巢癌患者在整个治疗过程中面临巨大的经济负担。

肿瘤治疗的经济负担很大，并且根据诊断阶段和治疗方法的不同而有很大差异。晚期诊断的患者通常比早期诊断的患者每年和累积的医疗费用更高。这种趋势在资料中很明显，晚期确诊患者的年平均医疗费用和累积医疗费用明显较高。各种癌症类型（尤其是卵巢癌）的 IV 期诊断的累积医疗费用显着增加，强调了早期检测的重要性。及时诊断可以实现更有效的治疗，这也有助于改善患者的治疗效果并降低医疗成本，从而进一步推动市场成长。

PARP 抑制剂生物标记市场报告亮点

  • 套件细分市场处于领先地位，2023 年销售额份额最高可达 65.35%。这是由于人们对有效诊断解决方案的认识不断提高。
  • 预计检测领域将在预测期内以最快的复合年增长率增长，因为它是 PARP 抑製剂生物标记开发和检验的重要组成部分，并允许研究人员和临床医生准确测量生物样本中的生物标誌物浓度。
  • 按服务划分，BRCA1&2检测领域在2023年以43.54%的最大收入份额引领市场。 PARP 抑制剂对 BRCA1 和 BRCA2 突变相关癌症的重要性日益增加，进一步增强了其重要性。
  • 从应用来看，乳癌细分市场以 2023 年最大的销售份额 48.42% 领先市场。预计卵巢癌细分市场在预测期内将以最快的复合年增长率成长。
  • 由于基因组技术的进步、高购买力平价、政府对优质医疗保健的支持以及对新诊断方法开发的资助等因素，北美在 2023 年以 43.95% 的销售份额占据市场主导地位。

目录

第一章调查方法与范围

第 2 章执行摘要

第 3 章 PARP 抑制剂生物标记市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/补充市场展望。
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • PARP抑制剂生物标记市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第 4 章 PARP 抑制剂生物标记市场：按产品估算和趋势分析

  • PARP 抑制剂生物标记市场：产品仪表板
  • PARP抑制剂生物标记市场：产品变异分析
  • PARP 抑制剂生物标记市场：按产品分類的收益
  • 套件
  • 化验

第五章 PARP抑制剂生物标记市场：按服务估算和趋势分析

  • PARP 抑制剂生物标记市场：服务仪表板
  • PARP抑制剂生物标记市场：服务变化分析
  • PARP 抑制剂生物标记市场：按服务分類的收益
  • BRCA 1 和 2 测试
  • 人力资源开发测试
  • 心率测试
  • 其他的

第六章 PARP抑制剂生物标记市场：应用、估算与趋势分析

  • PARP 抑制剂生物标记市场：应用仪表板
  • PARP抑制剂生物标记市场：应用变化分析
  • PARP 抑制剂生物标记市场：按应用分類的收益
  • 乳癌
  • 卵巢癌
  • 其他的

第七章 PARP抑制剂生物标记市场：区域估计和趋势分析

  • 区域仪表板
  • 2018-2030年市场规模、预测趋势分析
  • 北美洲
    • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 外交部
    • 外交部
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
    • 2023年主要企业市场占有率分析
    • Myriad Genetics, Inc.
    • Ambry Genetics
    • Thermo Fisher Scientific Inc.
    • Illumina, Inc.
    • CENTOGENE NV
    • Amoy Diagnostics Co., Ltd.
    • Invitae Corporation
    • NeoGenomics Laboratories.
    • QIAGEN
    • Agilent Technologies, Inc.
Product Code: GVR-4-68040-248-1

PARP Inhibitor Biomarkers Market Growth & Trends:

The global PARP inhibitor biomarkers market size is anticipated to reach USD 1,602.10 million by 2030 and is projected to grow at a CAGR of 8.54% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising incidence of breast cancer is a significant factor for market expansion in the PARP Inhibitors biomarkers sector. According to the WHO article published in 2022, increasing prevalence of cancer cases, with an estimated 20 million new cases of 9.7 million deaths reported. Despite advancements, the fight against cancer remains tough, with an estimated 53.5 million individuals surviving within 5 years of diagnosis. Moreover, Female breast cancer emerges as a significant concern, ranking second in global cases at 2.3 million (11.6%), accounting for 670,000 deaths (6.9%). Especially it stands as the most widespread among women across 157 out of 185 countries surveyed.

Advancements in genomic technologies have significantly contributed to developing and refining PARP inhibitor biomarkers. According to the NCBI article published in August 2021, these advancements have enabled researchers to identify and validate biomarkers that predict patients' response to PARP inhibitors, thereby facilitating personalized treatment strategies. A study developed a 3D functional assay to identify biomarkers predictive of the response to poly-ADP ribose polymerase inhibitors (PARPis) in high-grade serous ovarian cancer (HGSOC) patients. This approach allowed for a more accurate and comprehensive understanding of how cells respond to PARP inhibitors in a physiologically relevant environment.

The increasing expenditure for treatment and management fuels the market growth. According to the articleBioMed Central Ltd published in September 2022, particularly for breast and ovarian cancer, is a major issue influenced by several factors, including the stage of diagnosis, the specific treatments used, and the overall healthcare costs associated with cancer care. The provided sources offer insights into the financial burden of treatments and the factors contributing to their rising expenditure. Breast and ovarian cancer patients face significant financial burdens throughout their treatment journey.

The financial burden of oncology care can be significant and vary widely based on diagnosis stage and treatment methods. Patients diagnosed in later stages generally incur higher annual and cumulative healthcare expenses compared to those diagnosed earlier. This trend is evident in the data, showing notably higher mean annual and cumulative healthcare costs for patients diagnosed at later stages. The considerable rise in cumulative costs, particularly for stage IV diagnoses across various cancer types such as ovarian, emphasizes the critical importance of early detection. Timely diagnosis allows more effective treatment and also contributes to better patient outcomes and reduced healthcare expenditures further propelling market growth.

PARP Inhibitor Biomarkers Market Report Highlights:

  • The kits segment led the market with the largest revenue share of 65.35% in 2023. It is due to attributed of rising the awareness regarding effective diagnostics solutions
  • The assays segment is anticipated to grow at the fastest CAGR during the forecast period, owing to being a crucial component for developing and validating PARP inhibitor biomarkers, enabling researchers and clinicians to measure these biomarkers' levels in biological samples accurately
  • Based on services, the BRCA1 & 2 testing segment led the market with the largest revenue share of 43.54% in 2023, due to its critical role in treatment. The rise in importance of PARP inhibitors for BRCA1 and BRCA2 mutation-associated cancers has further boosted its significance
  • In terms of application, the breast cancer segment led the market with the largest revenue share of 48.42% in 2023. The ovarian cancer segment is anticipated to grow at the fastest CAGR during the forecast period
  • North America dominated the market with the revenue share of 43.95% in 2023, owing to factors such as advancement in genomic technologies, high purchasing power parity, government support for quality healthcare, and funding for development of novel diagnostics

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Services
    • 1.2.3. Application
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Services outlook
    • 2.2.3. Application outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. PARP Inhibitor Biomarkers Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of breast cancer
      • 3.2.1.2. Advancements in genomic technologies
      • 3.2.1.3. Rising expenditure for cancer treatment
      • 3.2.1.4. Growing adoption of personalized medicine and precision therapy
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of PARP inhibitor biomarker test kits and assays
      • 3.2.2.2. Limited awareness and understanding of PARP inhibitors biomarkers
  • 3.3. PARP Inhibitor Biomarkers Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. PARP Inhibitor Biomarkers Market: Product Estimates & Trend Analysis

  • 4.1. PARP Inhibitor Biomarkers Market: Product Dashboard
  • 4.2. PARP Inhibitor Biomarkers Market: Product Movement Analysis
  • 4.3. PARP Inhibitor Biomarkers Market by Product Revenue
  • 4.4. Kits
    • 4.4.1. Kits Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Assays
    • 4.5.1. Assays Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. PARP Inhibitor Biomarkers Market: Services Estimates & Trend Analysis

  • 5.1. PARP Inhibitor Biomarkers Market: Services Dashboard
  • 5.2. PARP Inhibitor Biomarkers Market: Services Movement Analysis
  • 5.3. PARP Inhibitor Biomarkers Market by Services Revenue
  • 5.4. BRCA 1 & 2 Testing
    • 5.4.1. BRCA 1 & 2 Testing Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. HRD Testing
    • 5.5.1. HRD Testing Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. HRR Testing
    • 5.6.1. HRR Testing Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. PARP Inhibitor Biomarkers Market: Application Estimates & Trend Analysis

  • 6.1. PARP Inhibitor Biomarkers Market: Application Dashboard
  • 6.2. PARP Inhibitor Biomarkers Market: Application Movement Analysis
  • 6.3. PARP Inhibitor Biomarkers Market by Application Revenue
  • 6.4. Breast Cancer
    • 6.4.1. Breast Cancer Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5. Ovarian Cancer
    • 6.5.1. Ovarian Cancer Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. PARP Inhibitor Biomarkers Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. North America
    • 7.3.2. U.S.
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe
    • 7.4.2. UK
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.7. Norway
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.9. Denmark
      • 7.4.9.1. Key country dynamics
      • 7.4.9.2. Regulatory framework
      • 7.4.9.3. Competitive scenario
      • 7.4.9.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific
    • 7.5.2. Japan
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.5. Australia
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.7. Thailand
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Regulatory framework
      • 7.5.7.3. Competitive scenario
      • 7.5.7.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America
    • 7.6.2. Brazil
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.3. Mexico
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.4. Argentina
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA
    • 7.7.2. South Africa
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. Myriad Genetics, Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Ambry Genetics
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Thermo Fisher Scientific Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Illumina, Inc.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. CENTOGENE N.V.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Amoy Diagnostics Co., Ltd.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Invitae Corporation
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. NeoGenomics Laboratories.
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. QIAGEN
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Agilent Technologies, Inc.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America PARP inhibitor biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
  • Table 5 North America PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 6 U.S. PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 7 U.S. PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
  • Table 8 U.S. PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 9 Canada PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 10 Canada PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
  • Table 11 Canada PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 12 Europe PARP inhibitor biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 14 Europe PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
  • Table 15 Europe PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 16 Germany PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 17 Germany PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
  • Table 18 Germany PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 19 UK PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 20 UK PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
  • Table 21 UK PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 22 France PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 23 France PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
  • Table 24 France PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 25 Italy PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 26 Italy PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
  • Table 27 Italy PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 28 Spain PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 29 Spain PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
  • Table 30 Spain PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 31 Denmark PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 32 Denmark PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
  • Table 33 Denmark PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 34 Sweden PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 35 Sweden PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
  • Table 36 Sweden PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 37 Norway PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 38 Norway PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
  • Table 39 Norway PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific PARP inhibitor biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 44 China PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 45 China PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
  • Table 46 China PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 47 Japan PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 48 Japan PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
  • Table 49 Japan PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 50 India PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 51 India PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
  • Table 52 India PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 53 South Korea PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 54 South Korea PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
  • Table 55 South Korea PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 56 Australia PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 57 Australia PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
  • Table 58 Australia PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 59 Thailand PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 60 Thailand PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
  • Table 61 Thailand PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 62 Latin America PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 63 Latin America PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
  • Table 64 Latin America PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 65 Brazil PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 66 Brazil PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
  • Table 67 Brazil PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 68 Mexico PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 69 Mexico PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
  • Table 70 Mexico PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 71 Argentina PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 72 Argentina PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
  • Table 73 Argentina PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 74 MEA PARP inhibitor biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 75 MEA PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 76 MEA PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
  • Table 77 MEA PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 78 South Africa PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 79 South Africa PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
  • Table 80 South Africa PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 81 Saudi Arabia PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 84 UAE PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 85 UAE PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
  • Table 86 UAE PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 87 Kuwait PARP inhibitor biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 88 Kuwait PARP inhibitor biomarkers market, by services, 2018 - 2030 (USD Million)
  • Table 89 Kuwait PARP inhibitor biomarkers market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 PARP inhibitor biomarkers market: market outlook
  • Fig. 14 PARP inhibitor biomarkers competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook.
  • Fig. 17 Industry value chain analysis
  • Fig. 18 PARP inhibitor biomarkers market driver impact
  • Fig. 19 PARP inhibitor biomarkers market restraint impact
  • Fig. 20 PARP inhibitor biomarkers market strategic initiatives analysis
  • Fig. 21 PARP inhibitor biomarkers market: Product movement analysis
  • Fig. 22 PARP inhibitor biomarkers market: Product outlook and key takeaways
  • Fig. 23 Kits market estimates and forecast, 2018 - 2030
  • Fig. 24 Assays market estimates and forecast, 2018 - 2030
  • Fig. 25 PARP inhibitor biomarkers market: Services movement analysis
  • Fig. 26 PARP inhibitor biomarkers market: Services outlook and key takeaways
  • Fig. 27 BRCA 1 & 2 Testing market estimates and forecasts, 2018 - 2030
  • Fig. 28 HRD Testing market estimates and forecasts,2018 - 2030
  • Fig. 29 HRR Testing market estimates and forecasts, 2018 - 2030
  • Fig. 30 Others market estimates and forecasts,2018 - 2030
  • Fig. 31 PARP inhibitor biomarkers market: Application movement analysis
  • Fig. 32 PARP inhibitor biomarkers market: Application outlook and key takeaways
  • Fig. 33 Breast Cancer market estimates and forecasts, 2018 - 2030
  • Fig. 34 Ovarian Cancer market estimates and forecasts,2018 - 2030
  • Fig. 35 Others market estimates and forecasts, 2018 - 2030
  • Fig. 36 Global PARP inhibitor biomarkers market: Regional movement analysis
  • Fig. 37 Global PARP inhibitor biomarkers market: Regional outlook and key takeaways
  • Fig. 38 Global PARP inhibitor biomarkers market share and leading players
  • Fig. 39 North America
  • Fig. 40 North America market estimates and forecasts, 2018 - 2030
  • Fig. 41 U.S. key country dynamics
  • Fig. 42 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 43 Canada key country dynamics
  • Fig. 44 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 45 Europe
  • Fig. 46 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 47 UK key country dynamics
  • Fig. 48 UK market estimates and forecasts, 2018 - 2030
  • Fig. 49 Germany key country dynamics
  • Fig. 50 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 51 France key country dynamics
  • Fig. 52 France market estimates and forecasts, 2018 - 2030
  • Fig. 53 Italy key country dynamics
  • Fig. 54 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 55 Spain key country dynamics
  • Fig. 56 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 57 Denmark key country dynamics
  • Fig. 58 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 59 Sweden key country dynamics
  • Fig. 60 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 61 Norway key country dynamics
  • Fig. 62 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 63 Asia Pacific
  • Fig. 64 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 65 China key country dynamics
  • Fig. 66 China market estimates and forecasts, 2018 - 2030
  • Fig. 67 Japan key country dynamics
  • Fig. 68 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 69 India key country dynamics
  • Fig. 70 India market estimates and forecasts, 2018 - 2030
  • Fig. 71 Thailand key country dynamics
  • Fig. 72 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 73 South Korea key country dynamics
  • Fig. 74 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 75 Australia key country dynamics
  • Fig. 76 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 77 Latin America
  • Fig. 78 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 79 Brazil key country dynamics
  • Fig. 80 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 81 Mexico key country dynamics
  • Fig. 82 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 83 Argentina key country dynamics
  • Fig. 84 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 85 Middle East and Africa
  • Fig. 86 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 87 South Africa key country dynamics
  • Fig. 88 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 89 Saudi Arabia key country dynamics
  • Fig. 90 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 91 UAE key country dynamics
  • Fig. 92 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 93 Kuwait key country dynamics
  • Fig. 94 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 95 Market share of key market players - PARP inhibitor biomarkers market